Literature DB >> 7945455

Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers.

P Wils1, V Phung-Ba, A Warnery, D Lechardeur, S Raeissi, I J Hidalgo, D Scherman.   

Abstract

The expression of the multidrug transporter P-glycoprotein has been studied in two human intestinal epithelial cell lines. No functional expression of P-glycoprotein was found in the differentiated HT29-18-C1 cell line. The expression of P-glycoprotein in the Caco-2 cell line was very high, as judged by immunoblotting and by active efflux of vinblastine. The polarized transport of vinblastine in the basolateral to apical direction was temperature and energy dependent, and was reduced by P-glycoprotein inhibitors such as verapamil, chlorpromazine and reserpine. This adds further evidence that the polarized transport of vinblastine across Caco-2 monolayers is mediated by P-glycoprotein. The anticancer drug docetaxel (Taxotere) was transported in a polarized manner: basolateral to apical permeability was 20-fold higher than in the reverse direction. This polarized transport was inhibited by verapamil, chlorpromazine and reserpine, thus demonstrating that docetaxel is a substrate of P-glycoprotein. The implications of these results for the pharmacokinetics and toxicity of taxoids are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945455     DOI: 10.1016/0006-2952(94)90580-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  29 in total

Review 1.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase.

Authors:  Wei-Ling Chang; Chih-Shiang Chang; Po-Cheng Chiang; Yunn-Fang Ho; Ju-Fang Liu; Kai-Wei Chang; Jih-Hwa Guh
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Docetaxel Induced Sclerosing Cholangitis.

Authors:  Jennifer L Horsley-Silva; Elizabeth N Dow; Christine O Menias; Maxwell L Smith; Estrella M Carballido; Keith D Lindor; Hugo E Vargas
Journal:  Dig Dis Sci       Date:  2015-12       Impact factor: 3.199

Review 4.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

5.  Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.

Authors:  J Alsenz; H Steffen; R Alex
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS).

Authors:  Yi-Dong Yan; Nirmal Marasini; Young Keun Choi; Jong Oh Kim; Jong Soo Woo; Chul Soon Yong; Han Gon Choi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-27       Impact factor: 2.441

Review 8.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

9.  Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

Authors:  V D Makhey; A Guo; D A Norris; P Hu; J Yan; P J Sinko
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

10.  In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin.

Authors:  A Crowe; M Lemaire
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.